KVUE Earnings Prediction
The chart below shows how KVUE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, KVUE sees a +0.24% change in stock price 10 days leading up to the earnings, and a +3.93% change 10 days following the report. On the earnings day itself, the stock moves by +0.58%. This data can give you a slight idea of what to expect for the next quarter's release.
KVUE Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
3.66B
-0.11%
-6.08%
Gross Margin
56.53%
-1.22%
-3.42%
Operating Margin
14.96%
-21.76%
-14.47%
Net Margin
8.00%
-10.31%
-18.53%
EPS
0.15
-11.76%
-25.00%
No Data Available
KVUE Earnings Analysis
Kenvue Inc Corporation (KVUE.N) Earnings Conference Call
Positive
Organic Sales Performance: Organic sales growth for the year was 1.5%, with adjusted diluted EPS for the year of $1.14, squarely within guidance range.
Gross Margin Improvement: Adjusted gross margin increased by 200 basis points year-over-year to 60.4%, driven by strong productivity enhancements in operations.
Brand Investment Increase: Total brand investment for the year increased by about 20%, supported by cost savings and gross margin improvement.
Self-Care Sales Growth: Self-care segment organic sales grew by 2.9% in Q4, with high single-digit growth excluding the pediatric pain franchise.
Skin Health Sales Growth: Skin health and beauty delivered volume-led 2.6% organic sales growth in Q4, with EMEA and Latin America driving double-digit growth.
Negative
Disappointing Organic Sales Growth: Organic sales growth for 2024 was only 1.5%, falling short of expectations due to lower incidences of cough, cold, and flu, particularly impacting the pediatric pain franchise.
Disappointing Sales Performance: In Q4, organic sales growth was just 1.7%, with a significant decline in pediatric pain sales, which contracted over 40% in China and nearly 11% in the US, leading to a disappointing overall performance.
Organic Sales Decline in Asia: Essential health segment organic sales decreased by 0.7% in Q4, primarily due to a reduction in customer orders in Asia Pacific, particularly China, indicating underlying demand issues in that region.
Organic Sales Growth Impact: Total company organic sales growth without the pediatric pain franchise would have been about two points higher in Q4 and one point higher for the full year 2024, highlighting the negative impact of this category's performance.
Organic Sales Decline Expected: The company expects organic sales to decline low single digits in Q1 2025 due to destocking and strategic price investments, indicating a challenging start to the year.
KVUE FAQs
How does KVUE typically perform around its earnings report dates?
Is Kenvue Inc (KVUE) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
KVUE Earning Call Sentiment
Kenvue Inc. (NYSE:KVUE) Q4 2024 Earnings Call Transcript
KVUE.N
0.69%Positive
The earnings call highlights several challenges: weak organic sales growth, distribution issues in Asia Pacific, and economic uncertainties. The lack of a share repurchase program and the operational separation risks add to investor concerns. Despite some positive elements like increased gross margin and brand investment, the overall sentiment is negative due to the financial outlook and management's vague responses during the Q&A. The absence of any strong positive catalysts, such as a new partnership or robust guidance, further supports a negative sentiment.
